HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

Cipla share price declined 2 percent after the United States Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI). At 09:29am, Cipla was quoting ...

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

HYDERABAD/BENGALURU, Jan 28 (Reuters) - Cipla (CIPL.NS), opens new tab, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong ...

Pharma major Cipla Ltd on Tuesday posted its highest-ever quarterly revenue and Ebitda margin, as robust sales in India, Europe and emerging markets outweighed weakness in its US business.

Shares traded at ₹358.05 on the NSE, down 2.09%. Cipla Ltd recorded its consolidated net profit for the quarter ended December 2024 at ₹1,574.59 crore as against ₹1,068.41 crore in the ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Cipla: The pharma player has informed the exchanges that its manufacturing facility in Bengaluru's Virgonagar has received a Voluntary Action Indicated status from the USFDA. VA Tech Wabag ...

Drug major Cipla on Tuesday reported a 49% jump in its December quarter consolidated net profit at Rs 1,571 crore as compared to Rs 1,056 crore reported in the year-ago period. The profit after tax ...

Cipla finished the day at Rs 1464.15, showing a fall of 1.22% in its market value. Cipla's shares are currently priced at Rs 1465.95, reflecting a 1.09% decrease today, alongside a return of 3.38% ...